Creative Biolabs has announced significant upgrades to its biosimilar development services and contract development and manufacturing organization platform. The enhancements focus on strengthening capabilities in physicochemical characterization and biological activity comparison, critical requirements for pharmaceutical companies that must demonstrate their biosimilar products are highly similar or statistically equivalent to reference drugs.
The company's platform now offers extensive physicochemical evaluations including primary sequence validation, high-order structure analysis, and charge variant analysis. For biological activity assessment, Creative Biolabs has established a series of cell-based functional experiments to ensure high consistency with original drugs in terms of binding affinity and downstream signal transduction. A chief researcher at the company explained that these capabilities are essential for meeting regulatory requirements for biosimilar approval.
Creative Biolabs is highlighting its experience developing biosimilar pipelines covering more than 20 popular varieties, focusing on the monoclonal antibodies market. The company's development catalogue includes analogues of globally best-selling drugs such as Rituximab, Trastuzumab, and Adalimumab. Beyond off-the-shelf solutions, the company addresses specific technical challenges, such as using proprietary high-expression cell line construction technology for Bevacizumab analogues to significantly increase production while optimizing downstream purification processes to remove trace impurities.
The company's one-stop CDMO solution provides flexible production support from molecular design to 2000 L large-scale production, breaking down barriers between research and commercialization. This platform supports not only monoclonal antibodies but also extends to bispecific antibodies, ADC drugs, and viral vectors. Key components include cell line development using platforms like CHO and HEK293 with high-yield stable clone screening, upstream process supporting bioreactor scales from 50L to 2000L, downstream process involving advanced protein A affinity chromatography, ion exchange, and virus filtration, and quality control with environmental monitoring according to GMP standards and a multi-dimensional quality detection system.
The researcher noted that many partners perform well in pilot stages but encounter yield reduction during scale-up, a challenge the platform specifically addresses. Through linear scale-up technology and single-use bioreactor systems, Creative Biolabs ensures process consistency from initial cloning to commercial GMP production, effectively reducing regulatory risk. The company's comprehensive approach aims to support both pharmaceutical giants and biotechnology startups in navigating the complex biosimilar development landscape while maintaining quality and efficiency throughout the production process.
